Phase II Trial of O6-Benzylguanine and Temozolomide in P

O6-苄基鸟嘌呤和替莫唑胺治疗 P 的 II 期试验

• 批准号: 7292867
• 负责人: Katherine e Warren
• 金额: --
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7292867
• 关键词: Phase; II; Trial; O6; Benzylguanine

A Phase II study of temozolomide (TMZ), combined with the AGT inhibitor, O6-benzylguanine (O6-BG), will be performed in pediatric patients with progressive or recurrent high-grade gliomas or brainstem gliomas to determine the activity of this drug combination in this patient population. O6-BG will be administered as a 60-minute intravenous (IV) infusion daily for 5 days of a 28-day course. TMZ capsules will be administered orally 30 minutes after completion of each O6-BG infusion.The primary objective is to determine the objective response rate to the combination of intravenous O6-BG and oral TMZ in children with progressive or recurrent high-grade gliomas or brainstem gliomas.

替莫唑胺（TMZ）以及AGT抑制剂O6-苄基瓜氨酸（O6-BG）的II期研究将在患有进行性或复发性高级神经胶质瘤或脑干神经胶质瘤的儿科患者中进行，以确定该患者人群中这种药物组合的活性。 O6-BG每天将以60分钟的静脉输注（IV）为28天的课程5天。每次O6-BG输注完成后30分钟口服TMZ胶囊。主要目的是确定静脉内O6-BG和口服TMZ的客观反应率在具有渐进或经常性高级神经胶质瘤或脑干Gliomas的儿童中。